Role of N-Terminal Pro B-Type Natriuretic Peptide (NT-proBNP) for Diagnosing Underlying Cardiac and Extra-cardiac Diseases in Patients presenting with Acute Breathlessness in the Emergency Department

  • Nalini Bala Pandey Consultant Emergency Medicine, Department of Obstetrics and Gynaecology, Lok Nayak Hospital, Delhi, India. https://orcid.org/0000-0003-0026-9563
  • Dina J Shah Director and Head of the Department, Department of Emergency Medicine, Fortis Hospital, Noida, Uttar Pradesh, India.
  • Parneesh Arora Additional Director, Department of Cardiology, Fortis Hospital, Noida, Uttar Pradesh, India.
  • AK Mathur Ex Scientist F, National Institute of Medical Statistics-Indian Council of Medical Research (ICMR), Delhi, India.
Keywords: Breathlessness, N-terminal pro-B-type Natriuretic Peptide, Heart Failure, Renal Failure, Sepsis

Abstract

Background: Utility of NT-proBNP in patients presenting with acute breathlessness in the Emergency Department (ED) is high.

Aim and Objectives: To evaluate the role of NT-proBNP for early diagnosis of underlying cardiac and extra-cardiac diseases (renal, sepsis and respiratory failure) for patients presenting with acute breathlessness in the ED. The primary objective was correlation of NT-proBNP for diagnosing underlying diseases and the secondary objective was to establish its cutoff value to diagnose underlying diagnosis.

Methods: A prospective observational study was conducted on 241 patients with acute breathlessness in ED. They were categorised into two groups based on NT-proBNP values: Group 1 (high) and Group 2 (normal)
as per their age-related pre-determined cut-offs. Correlation in terms of validity of NT-proBNP against underlying diagnosis and its diagnostic values were assessed. To estimate the cut-off value of NT-proBNP for underlying diseases, Receiver Operating Characteristics (ROC) curve was plotted.

Results: For underlying cardiac diseases, the cutoff value of NT-proBNP in ROC curve was 931.5 pg/ml (Sensitivity: 92.6%, Specificity: 68.0%, AUCs: 0.85, p < 0.001) and for renal diseases, the cutoff value of NT-proBNP was 2280 pg/ml (Sensitivity: 92.2%, Specificity: 76.1%, AUCs: 0.94, p < 0.001).

Conclusion: This study established the role of NT-proBNP in indicating cardiac and renal involvement in patients presenting with acute breathlessness in the ED. In addition, normal NT-proBNP values rules out underlying cardiac and renal involvement. Also, higher NT-proBNP levels are indicative of multi-system involvement.

How to cite this article:
Pandey NB, Shah DJ, Arora P, Mathur AK. Role of N-Terminal Pro B-Type Natriuretic Peptide (NTproBNP)
for Diagnosing Underlying Cardiac and Extra-cardiac Diseases in Patients presenting with Acute Breathlessness in the Emergency Department. J Adv Res Med. 2021;8(4):1-11.

DOI: https://doi.org/10.24321/2349.7181.202113

References

Tintinalli JE, Stapczynski JS, Ma OJ, Cline DM, Meckler GD, Yealy DM, editors. Tintinalli’s emergency medicine:

a comprehensive study guide. 8th ed. New York: McGraw-Hill Education; 2016 Mar 22.

Rudiger A, Gasser S, Fischler M, Hornemann T, von Eckardstein A, Maggiorini M. Comparable increase

of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with

severe sepsis, septic shock, and acute heart failure. Crit Care Med. 2006 Aug;34(8):2140-4. [PubMed] [Google

Scholar]

Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol. 2008 Sep;19(9):1643-

[PubMed] [Google Scholar]

Faggiano P, Valle R, Aspromonte N, D’Aloia A, Di Tano G, Barro S, Giovinazzo P, Milani L, Lorusso R, Dei Cas

L. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to

the hospital for acute severe heart failure?: Role of serial measurements to improve short-term prognostic

stratification. Int J Cardiol. 2010 Apr 1;140(1):88-94. [PubMed] [Google Scholar]

Wettersten N, Maisel AS. Biomarkers for heart failure: an update for practitioners of internal medicine. AmJ Med. 2016 Jun 1;129(6):560-7. [PubMed] [Google Scholar]

Mangla A. Brain-Type Natriuretic Peptide (BNP): Reference range, Interpretation. emedicine.medscape.

com update 2021 https://emedicine.medscape.com/article/2087425-overview

Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-proBNP): measurement and

relevance in heart failure. Vasc Health Risk Manag. 2010;6:411. [PubMed] [Google Scholar]

Januzzi Jr JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT,

Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB.

The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol.

Apr 15;95(8):948-54. [PubMed] [Google Scholar]

Sarzani R, Spannella F, Giulietti F, Fedecostante M, Giordano P, Gattafoni P, Espinosa E, Busco F, Piccinini

G, Dessì-Fulgheri P. NT-proBNP and its correlation with in-hospital mortality in the very elderly without

an admission diagnosis of heart failure. Plos One. 2016 Apr 14;11(4):e0153759. [PubMed] [Google Scholar]

Khezri BS, Carlsson L, Larsson A. Evaluation of the Alere NT‐proBNP Test for Point of Care Testing. J Clin Lab

Anal. 2016 Jul;30(4):290-2. [PubMed] [Google Scholar]

Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007 Dec 18;50(25):2357-68. [PubMed]

[Google Scholar]

Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J. 2010 Mar 1;51(2):151-63. [PubMed] [Google Scholar]

Hall C. Essential biochemistry and physiology of (NT‐pro) BNP. Eur J Heart Fail. 2004 Mar;6(3):257-60. [PubMed] [Google Scholar]

Bay M, Kirk V, Parner J, Hassager C, Nielsen H, Krogsgaard K, Trawinski J, Boesgaard S, Aldershvile J. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart. 2003 Feb 1;89(2):150-4. [PubMed] [Google Scholar]

Bayes‐Genis A, Santalo‐Bel M, Zapico‐Muniz E, Lopez L, Cotes C, Bellido J, Leta R, Casan P, Ordonez‐Llanos J.

N‐terminal probrain natriuretic peptide (NT‐proBNP) in the emergency diagnosis and in‐hospital monitoring of

patients with dyspnoea and ventricular dysfunction. Eur J Heart Fail. 2004 Mar;6(3):301-8. [PubMed] [Google

Scholar]

Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal–pro-brain natriuretic peptide

predicts outcome after hospital discharge in heart failure patients. Circulation. 2004 Oct 12;110(15):2168-

[PubMed] [Google Scholar]

Figal DA, Sanchez MC, Velasco JA, Pina TC, Gimeno LM, Rodriguez RG, Abizanda JA, Hernandez PM, Chavarri

MV. [Usefulness of NTproBNP in the emergency management of patients with severe dyspnea and

an uncertain heart failure diagnosis]. Rev Esp Cardiol. 2005 Oct;58(10):1155-61. Spanish. [PubMed] [Google

Scholar]

Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM,

Richards M. NT-proBNP testing for diagnosis and shortterm prognosis in acute destabilized heart failure: an

international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur

Heart J. 2006 Feb 1;27(3):330-7. [PubMed] [Google Scholar]

Srisawasdi P, Vanavanan S, Charoenpanichkit C, Kroll MH. The effect of renal dysfunction on BNP, NT-proBNP,

and their ratio. American journal of clinical pathology. 2010 Jan 1;133(1):14-23.[PubMed] [Google Scholar]

Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi Jr JL. Renal function,

congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the

ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol. 2006 Jan

;47(1):91-7. [PubMed] [Google Scholar]

Aacharya RP, Gastmans C, Denier Y. Emergency department triage: an ethical analysis. BMC Emerg

Med. 2011;11:16. [PubMed] [Google Scholar]

Heart failure- ACC clinical toolkit. Left Ventricular Ejection Fraction (LVEF). American College

of Cardiology 2014. https://www.acc.org/tools-and-practice-support/clinical-toolkits/~/media/1E4D8F9B69D14F55821BFE642FBFA221.ashx

Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiß C, Kaden JJ, Putensen C, Borggrefe M, Hoffmann

U. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis.

Circulation. 2005 Jul 26;112(4):527-34. [PubMed] [Google Scholar]

Hur M, Kim H, Lee S, Cristofano F, Magrini L, Marino R, Gori CS, Bongiovanni C, Zancla B, Cardelli P, Di Somma

S. Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic

peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis. BMC Infect

Dis. 2014 Dec;14(1):224. [PubMed] [Google Scholar]

Wang F, Wu Y, Tang L, Zhu W, Chen F, Xu T, Bo L, Li J, Deng X. Brain natriuretic peptide for prediction of

mortality in patients with sepsis: a systematic reviewand meta-analysis. Crit Care. 2012;16(3):R74. [PubMed]

[Google Scholar]

Mokart D, Sannini A, Brun JP, Faucher M, Blaise D, Blache JL, Faucher C. N-terminal pro-brain natriuretic

peptide as an early prognostic factor in cancer patients developing septic shock. Crit Care. 2007 Apr;11(2):R37.

[PubMed] [Google Scholar]

Ray P, Birolleau S, Lefort Y, Becquemin MH, Beigelman C, Isnard R, Teixeira A, Arthaud M, Riou B, Boddaert

J. Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis. Crit Care. 2006

Jun;10(3):R82. [PubMed] [Google Scholar]

Published
2021-12-30